Emtricitabine
Side effects
Options:
Show MedDRA Preferred Terms
Side effect
|
Data for drug
|
Placebo
|
Labels
|
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
Infection
|
44%
|
|
|
|
|
x
|
x
|
x
|
x
|
Skin hyperpigmentation
|
postmarketing, 32%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Cough increased
|
28%
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Otitis media
|
23%
|
|
|
|
|
x
|
x
|
x
|
|
Rhinitis
|
20%
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Body temperature increased
|
postmarketing, 18%
|
|
|
x
|
|
x
|
x
|
x
|
x
|
Pneumonia
|
15%
|
|
|
|
|
x
|
x
|
x
|
x
|
Diarrhoea
|
postmarketing — 5% - 20%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Fasting
|
2% - 24%
|
|
|
|
|
x
|
x
|
x
|
x
|
Gastroenteritis
|
11%
|
|
|
|
|
x
|
x
|
x
|
|
Abdominal pain
|
postmarketing — 10%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Rash
|
postmarketing — 9% - 21%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Fatigue
|
8%
|
|
|
|
|
x
|
x
|
x
|
x
|
Anaemia
|
postmarketing — 7% - 9.5%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Depression
|
7%
|
|
|
|
|
x
|
x
|
x
|
x
|
Dizziness
|
postmarketing — 7%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Nausea
|
postmarketing — 7% - 10%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Insomnia
|
postmarketing — 7%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Headache
|
postmarketing — 5% - 10.2%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Hyperbilirubinaemia
|
postmarketing, common
|
|
x
|
|
x
|
|
|
|
|
Upper respiratory tract infection
|
5%
|
|
|
|
|
x
|
x
|
x
|
x
|
Vomiting
|
postmarketing — 5% - 23%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Alanine aminotransferase increased
|
postmarketing, common
|
|
x
|
|
x
|
|
x
|
|
|
Sinusitis
|
4%
|
|
|
|
|
x
|
x
|
x
|
x
|
Nasopharyngitis
|
3%
|
|
|
|
|
x
|
x
|
x
|
x
|
Asthenia
|
postmarketing, common
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Dyspepsia
|
postmarketing, common
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Hypersensitivity
|
postmarketing, common
|
|
x
|
|
x
|
|
|
x
|
x
|
Hypertriglyceridaemia
|
postmarketing, common
|
|
x
|
|
x
|
|
|
|
|
Neutropenia
|
postmarketing, common
|
|
x
|
x
|
|
|
|
|
|
Pain
|
postmarketing, common
|
|
x
|
|
|
|
|
|
x
|
Pruritus
|
postmarketing, common
|
|
x
|
x
|
x
|
|
|
x
|
|
Urticaria
|
postmarketing, common
|
|
x
|
x
|
x
|
|
|
x
|
|
Rash pustular
|
postmarketing, common
|
|
x
|
x
|
x
|
|
|
x
|
|
Amylase increased
|
postmarketing, common
|
|
x
|
|
|
|
x
|
|
x
|
Vesiculobullous rash
|
postmarketing, common
|
|
x
|
x
|
x
|
|
|
x
|
|
Abnormal dreams
|
postmarketing, common
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Rash maculo-papular
|
postmarketing, common
|
|
x
|
x
|
x
|
|
|
x
|
|
Haematuria
|
2% - 3%
|
|
|
|
x
|
x
|
x
|
x
|
x
|
Glycosuria
|
1%
|
|
|
|
|
x
|
x
|
x
|
x
|
Hyperglycaemia
|
postmarketing — 1% - 2%
|
|
x
|
|
x
|
x
|
x
|
x
|
x
|
Angioedema
|
postmarketing, uncommon
|
|
x
|
|
|
|
|
|
x
|
Lactic acidosis
|
postmarketing
|
|
x
|
x
|
|
x
|
x
|
x
|
x
|
Autoimmune disorder
|
postmarketing
|
|
x
|
|
|
|
|
|
|
Mental disorder
|
postmarketing
|
|
x
|
|
x
|
x
|
x
|
x
|
x
|
Connective tissue disorder
|
postmarketing
|
|
x
|
|
|
|
|
|
x
|
Gastrointestinal disorder
|
postmarketing
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Basedow's disease
|
postmarketing
|
|
x
|
|
|
|
|
|
|
Hepatitis
|
postmarketing
|
|
x
|
|
|
|
|
|
x
|
Hepatomegaly
|
postmarketing
|
|
x
|
|
|
x
|
x
|
x
|
x
|
Hypercholesterolaemia
|
postmarketing
|
|
x
|
|
|
|
|
|
|
Hypertrophy of breast
|
postmarketing
|
|
x
|
|
|
|
|
|
|
Immune system disorder
|
postmarketing
|
|
x
|
|
|
|
|
|
x
|
Inflammation
|
postmarketing
|
|
x
|
x
|
x
|
|
|
|
|
Insulin resistance
|
postmarketing
|
|
x
|
|
|
|
|
|
|
Lipodystrophy
|
postmarketing
|
|
x
|
|
|
|
|
|
|
Nervous system disorder
|
postmarketing
|
|
x
|
|
x
|
x
|
x
|
x
|
x
|
Opportunistic infection
|
postmarketing
|
|
x
|
|
|
|
|
|
|
Osteonecrosis
|
postmarketing
|
|
x
|
|
|
|
|
|
|
Pancreatitis
|
postmarketing
|
|
|
x
|
|
|
|
|
x
|
Thrombocytopenia
|
postmarketing
|
|
|
x
|
|
|
|
|
|
Skin discolouration
|
postmarketing — 31.8%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Malnutrition
|
postmarketing
|
|
x
|
x
|
|
|
|
|
x
|
Unspecified disorder of skin and subcutaneous tissue
|
postmarketing
|
|
x
|
|
x
|
x
|
x
|
x
|
x
|
Function kidney decreased
|
postmarketing
|
|
x
|
|
|
|
|
|
|
Hepatobiliary disease
|
postmarketing
|
|
x
|
|
|
|
|
|
x
|
Infection mixed
|
postmarketing
|
|
x
|
|
x
|
|
|
|
|
Buffalo hump
|
postmarketing
|
|
x
|
|
|
|
|
|
|
Hyperlactacidaemia
|
postmarketing
|
|
x
|
|
|
|
|
|
|
Blood and lymphatic system disorders
|
postmarketing
|
|
x
|
x
|
|
|
|
|
|
Renal impairment
|
postmarketing
|
|
x
|
|
|
|
|
|
|
Hepatic steatosis
|
postmarketing
|
|
x
|
|
|
|
|
|
x
|
Anxiety
|
|
|
|
|
|
|
|
|
x
|
Arthralgia
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Back pain
|
|
|
|
|
|
|
|
|
x
|
Breast disorder
|
|
|
|
|
|
|
|
|
x
|
Anogenital warts
|
|
|
|
|
|
|
|
|
x
|
Depressive disorder
|
|
|
|
x
|
x
|
x
|
x
|
x
|
|
Dyspnoea
|
|
|
|
|
|
|
|
|
x
|
Fanconi syndrome
|
|
|
|
|
|
|
|
|
x
|
Fracture
|
|
|
|
|
|
|
|
|
x
|
Hepatitis B
|
|
|
|
|
|
x
|
x
|
x
|
x
|
Hypokalaemia
|
|
|
|
|
|
|
|
|
x
|
Renal failure acute
|
|
|
|
|
|
|
|
|
x
|
Nephrosis lower nephron
|
|
|
|
|
|
|
|
|
x
|
Mediastinal disorder
|
|
|
|
|
|
|
|
|
x
|
Myopathy
|
|
|
|
|
|
|
|
|
x
|
Nephritis interstitial
|
|
|
|
|
|
|
|
|
x
|
Neuritis
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Osteomalacia
|
|
|
|
|
|
|
|
|
x
|
Paraesthesia
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Neuropathy peripheral
|
|
|
|
|
|
|
|
|
x
|
Pharyngitis
|
|
|
|
|
|
|
|
|
x
|
Polyuria
|
|
|
|
|
|
|
|
|
x
|
Proteinuria
|
|
|
|
|
|
|
|
|
x
|
Prurigo
|
|
|
|
|
|
|
|
x
|
|
Renal failure
|
|
|
|
|
|
|
|
|
x
|
Rhabdomyolysis
|
|
|
|
|
|
|
|
|
x
|
Syphilis
|
|
|
|
|
|
|
|
|
x
|
Urethritis
|
|
|
|
|
|
|
|
|
x
|
Urinary tract infection
|
|
|
|
|
|
|
|
|
x
|
Urinary tract disorder
|
|
|
|
|
|
|
|
|
x
|
Weight decreased
|
|
|
|
|
|
|
|
|
x
|
Hypophosphataemia
|
|
|
|
|
|
|
|
|
x
|
Secondary syphilis
|
|
|
|
|
|
|
|
|
x
|
Genital ulceration
|
|
|
|
|
|
|
|
|
x
|
Creatine phosphokinase increased
|
|
|
|
|
|
x
|
x
|
x
|
|
Creatinine increased
|
|
|
|
|
|
|
|
|
x
|
Muscular weakness
|
|
|
|
|
|
|
|
|
x
|
Bone pain
|
|
|
|
|
|
|
|
|
x
|
Haemoglobin decreased
|
|
|
|
|
x
|
x
|
x
|
x
|
|
Nephrogenic diabetes insipidus
|
|
|
|
|
|
|
|
|
x
|
Rash macular
|
|
|
|
|
|
|
|
x
|
|
Rash vesicular
|
|
|
|
|
|
|
|
x
|
|
Myalgia
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Blood creatinine increased
|
|
|
|
|
|
|
|
|
x
|
Neuropathy
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
Rash generalised
|
|
|
|
|
|
|
|
x
|
|
Lipase increased
|
|
|
|
|
|
x
|
x
|
x
|
|
Infestation NOS
|
|
|
|
|
|
x
|
x
|
x
|
x
|
Glucose low
|
|
|
|
|
|
x
|
x
|
x
|
|
Exfoliative rash
|
|
|
|
|
|
|
|
x
|
|
Indications
Information about indications was extracted from the indications and usage sections of the labels.
Side effects: | 55 |
Source: | EMA |
---|
Side effects: | 36 |
Source: | Health Canada |
---|
Side effects: | 40 |
Source: | Medsafe |
---|
Side effects: | 48 |
Source: | FDA Structured Product Label |
---|
Side effects: | 50 |
Source: | FDA Structured Product Label |
---|
Side effects: | 59 |
Source: | FDA |
---|
Side effects: | 85 |
Source: | FDA Structured Product Label |
---|
Color scheme:
standard – alternative
|
|
100%
|
|
|
75%
|
|
|
50%
|
|
|
10%
|
|
|
frequent (1% to 100%)
|
|
|
infrequent (0.1% to 1%)
|
|
|
rare (<0.1%)
|
|
|
postmarketing
|
|
|
0%
|
|
|
no frequency information
|
|
|
not found on label
|